Navigation Links
Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Date:10/4/2007

Lead Compound Produces Significant LDL-Cholesterol Reduction and Weight

Loss When Combined with Zetia(R) in Hypercholesterolemic Patients

BRIDGEWATER, N.J., Oct. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic diseases, today announced final results of Phase II clinical trials involving its lead cholesterol management compound, an MTP-inhibitor, AEGR-733 either alone or in combination with ezetimibe (brand name: Zetia(R)*). The data were presented in two posters at the XVI International Symposium on Drugs Affecting Lipid Metabolism (DALM) (October 4-7, 2007, New York, NY), jointly sponsored by the Weill Cornell Medical College (New York, NY) and the Giovanni Lorenzini Medical Foundation (Milan, Italy and Houston, TX).

In the study measuring LDL-cholesterol (LDL-C, or "bad cholesterol") reduction, patients treated with a combination 10 mg of ezetimibe and 10 mg AEGR-733 experienced LDL-C reductions of 46%. Patients treated with 10 mg of ezetimibe alone experienced a 20% reduction in LDL-C levels. Significantly greater reductions in total cholesterol, non-HDL-cholesterol, Lp(a), and apoB were observed in the group receiving combined AEGR-733 and ezetimibe. There was no difference in the rate of discontinuations between the groups treated with AEGR-733 plus ezetimibe versus those treated with ezetimibe alone.

In a separate analysis of these data, the ability of AEGR-733 alone or in combination with ezetimibe was assessed for its ability to cause weight loss. Over the course of this study, patients were counseled on a low fat/low cholesterol diet but with no emphasis on total calories or weight reduction. Drug treatment consisted of ezetimibe alone (10 mg), AEGR-733 in escalating doses at 5 mg, then 7.5 mg, then 10 mg, or a combination of the two drugs for 12 weeks. Weight was monitored over the course of the study.

By 12 weeks, subjects rec
'/>"/>

SOURCE Aegerion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
11. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... DIEGO , Aug. 20, 2014 Trovagene, ... diagnostics, announced today that results from two clinical studies ... conference for the Company,s urine-based diagnostic test for the ... The IPV conference is scheduled to take place in ... to 25 th . Additionally, a new U.S. ...
(Date:8/20/2014)... Phase I Trial of Plasma ... KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a ... it has begun a Phase I, First in Human, ... the treatment of DME. The study,s Principal Investigator is ... Joslin Diabetes Center; Harvard Medical School Department of Ophthalmology, ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... conjunction with DURECT Corporation,s (Nasdaq: DRRX ) fourth ... listen to the conference call that will be broadcast live ... pm Eastern Time (1:30 pm Pacific Time). (Logo: ... the presentation will be available by accessing DURECT,s homepage at ...
... -- The SimplyGo Portable Oxygen Concentrator by Philips ... continuous flow and pulse does at a weight of only ... lightest weight continuous flow portable concentrator weighed in at a ... voltage meaning anywhere you go in the world you can ...
Cached Medicine Technology:SimplyGo Portable Oxygen Concentrator Now Available 2
(Date:8/21/2014)... 2014 The employees of Pharmica ... Washington Crossing, Pennsylvania on Thursday, August 7th to spend ... been looking for different ways that Pharmica could get ... with Pharmica Consulting. “When we heard that we could ... we jumped at the opportunity.” , Pharmica spent their ...
(Date:8/21/2014)... 21, 2014 Sometimes you have to lose the ... new book “From Zero to a Hundred: Finding My Purpose through ... story of surviving a broken family, a childhood of gang violence ... who you were created to be,” Roy said. “I didn’t give ... I know my purpose today of helping others overcome their trials.” ...
(Date:8/21/2014)... Michael E. Steuer , local doctor in ... the Bluff City with recent philanthropy at local synagogue. “The ... United States,” says friend and Rabbi David Julian of Or ... as providing in-house for the needy and teaching Hebrew to ... the local synagogue. And to remain close with the development ...
(Date:8/21/2014)... Drake University’s Phi Gamma Delta (FIJI) and ... cancer research, according to Billy Cundiff, President of Colleen’s ... for the Cleveland Browns, says the money raised by ... Dream Foundation and will fund research to be conducted ... Division of Gynecologic Oncology at the University of Iowa’s ...
(Date:8/21/2014)... Recently, BambooIndustry.com, one of the most famous ... new range of hand scraped bamboo floorings ... an Autumn special offer for these elegant items. According ... a discounted price, up to 25% off; the promotion ... , Providing natural looks and available in different varieties, ...
Breaking Medicine News(10 mins):Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 3Health News:Cheap Hand Scraped Bamboo Floorings Recently Unveiled by BambooIndustry.com 2
... Anderson Hospital administration and their ED process improvement ... the ED Patient Throughput Team at ... The ED Patient Throughput Team, responsible for reducing wait times ... three finalists to receive the award for their excellence in ...
... higher in moms-to-be who snore, study finds , THURSDAY, June ... more likely to develop gestational diabetes, new research has found. ... survey when they were between six and 20 weeks pregnant, ... that pregnant women who were frequent snorers -- defined as ...
... ... him uniquely qualified to lead NVCI , ... Las Vegas, NV (PRWEB) June 11, 2009 -- Stephen J. ... as Chairman of the Board for the Nevada Cancer Institute (NVCI) effective July 1, ...
... As a result of the economic climate, high-technology and ... in addition to extending cost controls for their current ... Aon Consulting,s Radford, a leading provider of compensation intelligence ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) , ...
... had best results in study , THURSDAY, June 11 (HealthDay ... diabetes, may also help non-diabetic obese people lose weight when ... Researchers divided 152 obese men and women (with a body-mass ... 241 pounds) into two groups. About 25 percent of the ...
... Researchers at Nationwide Children,s Hospital and Johns Hopkins University ... highly expressed in normal tissues but lost in diseased ... (miRNA) are a class of small RNA molecules that ... in gene expression and in maintaining normal cell development ...
Cached Medicine News:Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 2Health News:Anderson ED Team Receives Pinnacle Award for Excellence in Customer Service 3Health News:Frequent Snoring in Pregnancy Could Signal Blood Sugar Trouble 2Health News:Nevada Cancer Institute Names Stephen J. Cloobeck Chairman of the Board 2Health News:Nevada Cancer Institute Names Stephen J. Cloobeck Chairman of the Board 3Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 2Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 3Health News:Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate, Says Aon Consulting's Radford 4Health News:Diabetes Drug Byetta May Aid Weight Loss in Obese Patients 2Health News:Study shows promise for new cancer-stopping therapy 2
... easy-to-use 3800 and 3900/P pulse oximeters ... the proprietary clinical patient motion algorithm ... improved performance:, ,The 3800 and ... rigorous environmental/ mechanical stress testing such ...
... The Acuity LT Central Monitoring Station provides ... and ready to go right out of ... surveillance in specific care areas rather than ... ICU. As patient-to-caregiver ratios continue to climb ...
... 3800 and 3900/P pulse oximeters are ... proprietary clinical patient motion algorithm from ... performance:, ,The 3800 and 3900 ... environmental/ mechanical stress testing such as ...
... Researchers., ,S/5 Collect and S/5 Collect4 provides ... collect data from Datex-Ohmeda monitors. Data can be ... intervals. With S/5 Collect you have ability to ... interface cable or connect directly from S/5 Central. ...
Medicine Products: